Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous D-CIK cells in relapsed/refractory solid tumors
ChiCTR-OIC-17011679Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- Jun 2017
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dendritic cell vaccine + cytokine-induced killer cells in bronchial carcinoma, liver cancer, breast cancer and 4 more, sponsored by The First Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Overall survival rate. Started Jun 2017; status: recruiting.
02
Drugs
dendritic cell vaccine + cytokine-induced killer cells
03
Conditions
bronchial carcinomaliver cancerbreast cancerovarian cancerclear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on ChiCTR-OIC-17011679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-17011679.